The
company said on Tuesday that it expected to record pre-tax
restructuring charges of $2.0 billion to $2.4 billion in connection with
these plans, of which about $600 million will be recorded in the fourth
quarter of 2015.
Leerink
analysts said the announcement meant that an acquisition was still on
the cards for J&J, given that it had about $37 billion in cash as of
the end of the third quarter.
"We
continue to believe JNJ is an active acquirer with a focus likely
heavily weighted toward it's lagging Medical Devices business...it's a
matter of when, not if, JNJ does a deal", they wrote in a note.
J&J
also reiterated its full-year 2015 forecast, and said the restructuring
in the devices business move would not impact the $10 billion share
repurchase program.
The
company said the restructuring would affect its orthopaedics, surgery
and cardiovascular businesses within the larger medical devices unit.
The consumer medical devices, vision care and diabetes care, part of the same division, would not be affected, JNJ said.
The
restructuring is expected to result in annualized pre-tax cost savings
of $800 million to $1 billion, J&J said. Most of these savings are
expected by the end of 2018, including about $200 million in 2016.
New
Brunswick, New Jersey-based J&J currently employs about 60,000
within its medical devices unit, part of a global workforce of about
127,000.
The Band-Aid maker is expected to report its fourth quarter results on Jan. 26.
The company's shares rose about 1 percent to $98.25 in premarket trading.
By: Reuters.
Reporting: Natalie Grover (Bengaluru).
Editing: Ted Kerr, Robin Paxton and Savio D'Souza.
Review: Emerging Market Formulations & Research Unit, Flagship Records.
For The #FacebookTeam
For The #FacebookTeam